Publications by authors named "Mark Dunphy"

Claim this Profile
D
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido, Mark P Dunphy

JCO Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, Jonathan Kuten, Audrey Mauguen, Mark P Dunphy

J Nucl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis.
Maria Thor, Aditya Apte, Milan Grkovski, Charles B Simone, Daphna Y Gelblum, Mark Dunphy

Phys Imaging Radiat Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients.
Milan Grkovski, Mariza Daras, Tejus Bale, Serge Lyashchenko, Anne S Reiner, Mark P S Dunphy

EJNMMI Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [Lu]Lu-PSMA-617.
Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, Luke R G Pike, Milan Grkovski, Mark P S Dunphy

J Nucl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.
Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido, Mark P Dunphy

medRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epichaperome-targeted myocardial imaging by I-PU-H71 PET.
Sonia Mahajan, Milan Grkovski, Kevin D Staton, Susana Ravassa, Kwaku Domfe, Mark P Dunphy

Clin Transl Imaging· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
Feng-Ming Spring Kong, Chen Hu, Daniel A Pryma, Fenghai Duan, Martha Matuszak, Mark Dunphy

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly

medRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.
Nitya Raj, Kelley Coffman, Tiffany Le, Richard Kinh Gian Do, Johnathan Rafailov, Mark Dunphy

Neuroendocrinology· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment.
Jasmin Sponagel, Jill K Jones, Cheryl Frankfater, Shanshan Zhang, Olivia Tung, Mark P Dunphy

Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Y Particle Density Improves Outcomes After Radioembolization.
Aaron W P Maxwell, Humberto G Mendoza, Matthew J Sellitti, Juan C Camacho, Amy R Deipolyi, Mark P Dunphy

Cardiovasc Intervent Radiol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Optimizing Y Particle Density Improves Outcomes After Radioembolization.
Aaron W P Maxwell, Humberto G Mendoza, Matthew J Sellitti, Juan C Camacho, Amy R Deipolyi, Mark P Dunphy

Cardiovasc Intervent Radiol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
James J Harding, Melinda Telli, Pamela Munster, Martin H Voss, Jeffrey R Infante, Mark Dunphy

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system.
Alexander Bolaender, Danuta Zatorska, Huazhong He, Suhasini Joshi, Sahil Sharma, Mark P Dunphy

Nat Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Jonathan W Riess, Paul Frankel, David Shackelford, Mark Dunphy, Ramsey D Badawi

Clin Lung Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.
Simone Krebs, Darren R Veach, Lukas M Carter, Milan Grkovski, Monica Fornier, Mark P S Dunphy

J Nucl Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Tumor Epichaperome Expression Using [I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Komal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, Rui Wang, Elizabeth Comen, Mark P Dunphy

JCO Precis Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Mark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi

Clin Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.
Mark P S Dunphy, Nagavarakishore Pillarsetty

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and first-in-human-brain-cancer applications of [F]poly (ADP-ribose) polymerase inhibitor PET/MR.
Robert J Young, Paula Demétrio De Souza França, Giacomo Pirovano, Anna F Piotrowski, Philip J Nicklin, Mark P Dunphy

Neurooncol Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Feasibility of PARP1/2 Imaging with F-PARPi in Patients with Head and Neck Cancer.
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, Eva Burnazi, Sheryl Roberts, Mark P Dunphy

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Matthew D Hellmann, Barzin Y Nabet, Hira Rizvi, Aadel A Chaudhuri, Daniel K Wells, Mark P S Dunphy

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of [F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab.
Maya S Graham, Simone Krebs, Tejus Bale, Kwaku Domfe, Stephanie M Lobaugh, Mark P Dunphy

Neurooncol Adv· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis